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Podium Presentations: Thursday, July 18, 2019P1634from0.18 to 0.54, after correcting for age, sex and scanner (Table 2).
The mean global SUVR was significantly higher in APOE ε4 car-
riers (1.61) when compared to non-carriers (1.30) (p<.001). There
were no significant genetic (A) or environmental (E) correlations
between global SUVR and markers of SVD (Figure). The genetic
correlation between WMHV and PSMD was significant (0.64;
95% CI 0.41, 0.82). Conclusions: Amyloid load in the brains of
cognitively normal older people has moderate heritability with sug-
gestion of strong environmental influences. Whilst amyloid and
SVD pathology commonly co-occur, the role of shared genetic fac-
tors appears to be minimal. References: 1. Sachdev, P. S. et al.
(2009). Twin Research and Human Genetics, 12(6): 573-582.
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Background: USMedicare claims data suggest that prevalence rates
of Alzheimer’s disease and related dementias are 30% higher
among non-Hispanic Blacks and 14% higher among Hispanics
than among non-Hispanic Whites. However, claims-based esti-
mates may understate racial and ethnic differences in dementia
prevalence due to diagnosis disparities. This study used a modeling
approach with survey data to estimate dementia prevalence rates by
race/ethnicity and changes over time. Methods: Using survey re-
sponses to the Health and Retirement Study, we identified individ-
uals age70 with dementia based on a prediction model developed
by Hurd and colleagues. The ordered probit model predicts cogni-
tive status separately for self- and proxy-respondents as either ‘de-
mentia’, ‘cognitive impairment no dementia’, or ‘normal’ based on
age, gender, education, functional limitations, and imputed cogni-
tive scores. We analyzed predicted dementia prevalence rates by
race/ethnicity in years 2000-2014. Among individuals identified
as having dementia, we examined trends in awareness of one’s de-
mentia status (i.e., whether they recalled receiving an AD/memory
problem/dementia diagnosis from their doctor) by race/ethnicity.
All analyses adjusted for sampling weights. Results: Predicted de-
mentia prevalence was highest among non-Hispanic Blacks (Range
2000-2014: 18.7%-21.4%), followed by Hispanics (14.9%-19.7%)
and non-Hispanic Whites (10.2%-11.7%). Dementia prevalence
decreased steadily between 2000-2014, especially among non-His-
panic Blacks (from 21.4% to 18.7%). Among those predicted as
having dementia, 39%-47% reported they were informed of the
dementia status by their doctor. Knowledge about one’s dementia
status was poorer among Hispanics (30.5%-45.5%) and non-
Hispanic Blacks (35.4%-47.7%) than among non-Hispanic Whites
Podium Presentations: Thursday, July 18, 2019 P1635(39.4%-48.1%). Among subjects identified as having dementia,
self-respondents were less aware of their disease status than
proxy-respondents. Conclusions: Model prediction results suggest
that non-Hispanic Blacks are about 1.8 times and Hispanics are
1.6 times as likely to have dementia as non-Hispanic Whites.
Model-predicted differences in dementia prevalence by race/
ethnicity are greater compared to claims-based differences, sug-
gesting a higher frequency of undiagnosed dementia among non-
Hispanic Blacks and Hispanics. Less than half of model-identified
dementia subjects know they have the condition, though this pro-
portion varies by respondent type. Despite non-Hispanic Blacks
and Hispanics having higher prevalence, our findings show that
these groups may be less aware of their dementia status compared
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ppedroza@uw.eduBackground: There were approximately forty five million people
living with Alzheimer’s disease and other dementias around the
world in 2017. Treatment for patients with dementia is costly and
it is often not covered by insurance or formal healthcare systems.
The cost of dementia already poses a major economic burden on
the care systems in developed countries and it is increasing in devel-
oping countries. Comparable estimates of spending on Alzheimer’s
and other dementias are necessary to help allocate scarce healthcare
resources and efficiently treat this vulnerable population.Methods:
We conducted a systematic review on the treatment cost of Alz-
heimer’s disease and other dementias. We searched PubMed and
Google Scholar for disease expenditure and cost of illness studies
published between 2000 and 2016. 275 studies were identified for
extraction after appraisal for methodological quality. Total and
per-capita direct and indirect cost were extracted as well as data
on informal care. Cost data from the World Mental Health Surveys
was also included in our model. Country level prevalence, GDP, and
wage data were obtained from the Global Burden of Disease, In-
juries, and Risk Factors Study (GBD). Spatiotemporal Gaaussian
process regression was used to generate complete and comparable
estimates for Alzheimer’s and other dementias spending in 188
countries. All estimates are adjusted for the effects of inflation
and are reported in the 2018 purchasing power parity-adjusted dol-
lars. Results: The global cost of Alzheimer’s disease and other de-
mentias will exceed one trillion PPP dollars in 2018. Close to eighty
per cent of the costs occurred in high-income countries, with less
than 50% of the prevalence. The majority of the costs are informal,
reflecting the heavy economic burden of indirect and social care.
Conclusions: Care for Alzheimer’s disease and other dementias
pose an enormous economic burden for healthcare systems around
the world. Cost will continue to increase due to aging populations
and emerging treatments. Comprehensive, comparable cost esti-
mates are an excellent tool for policy makers worldwide. They
are helpful to learn from the spending practices of other countries
as well as to better allocate the resources of in their own health
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Background: Internationally, health systems strive to enable per-
sons with Alzheimer’s and related dementias (hereafter, dementia)
to remain at home to maximize their quality of life and, where
appropriate, to reduce the use of costly inpatient health services.
There is limited evidence describing long-term trajectories of
health system use by persons with dementia as they remain in the
